The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: A community based study in Southwest of Iran

Reproductive Biology and Endocrinology

Volumn 12, Issue 1, 2014, Pages

  Ramezani Tehrani, Fahimeh ^a   Rashidi, Homeira ^b   Bahri Khomami, Mahnaz ^a   Tohidi, Maryam ^c   Azizi, Fereidoun ^d  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Metabolic disorders; Metabolic syndrome; PCOS; Phenotype

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; CHOLESTEROL; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN; PRASTERONE SULFATE; PROLACTIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ANDROSTENEDIONE BLOOD LEVEL; ANOVULATION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; INSULIN BLOOD LEVEL; IRAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC DISORDER; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PROLACTIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84907274489     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-12-89     Document Type: Article

References (35)

1. Moran C, Arriaga M, Rodriguez G, Moran S. Obesity differentially affects phenotypes of polycystic ovary syndrome. Int J Endocrinol 2012, 2012:317241. 3399368, 22829818.
2. Gluszak O, Stopinska-Gluszak U, Glinicki P, Kapuscinska R, Snochowska H, Zgliczynski W, Debski R. Phenotype and metabolic disorders in polycystic ovary syndrome. ISRN Endocrinol 2012, 2012:569862. 3302054, 22462015.
3. Zhao Y, Fu L, Li R, Wang LN, Yang Y, Liu NN, Zhang CM, Wang Y, Liu P, Tu BB, Zhang X, Qiao J. Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis. BMC Med 2012, 10:153. 10.1186/1741-7015-10-153, 3599233, 23198915.
4. Koiou E, Tziomalos K, Dinas K, Katsikis I, Kandaraki EA, Tsourdi E, Mavridis S, Panidis D. Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome. Endocr J 2012, 59(1):21-29. 10.1507/endocrj.EJ11-0023, 21996594.
5. Hwang KR, Choi YM, Kim JJ, Chae SJ, Park KE, Jeon HW, Ku SY, Kim SH, Kim JG, Moon SY. Effects of insulin-sensitizing agents and insulin resistance in women with polycystic ovary syndrome. Clin Exp Reprod Med 2013, 40(2):100-105. 10.5653/cerm.2013.40.2.100, 3714427, 23875167.
6. Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, Spinas GA, Carmina E. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod 2009, 24(9):2286-2292. 10.1093/humrep/dep121, 19454589.
7. Guo M, Chen ZJ, Eijkemans MJ, Goverde AJ, Fauser BC, Macklon NS. Comparison of the phenotype of Chinese versus Dutch Caucasian women presenting with polycystic ovary syndrome and oligo/amenorrhoea. Hum Reprod 2012, 27(5):1481-1488. 10.1093/humrep/des018, 22402209.
8. Gambineri A, Pelusi C, Manicardi E, Vicennati V, Cacciari M, Morselli-Labate AM, Pagotto U, Pasquali R. Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes 2004, 53(9):2353-2358. 10.2337/diabetes.53.9.2353, 15331545.
9. Xiang SK, Hua F, Tang Y, Jiang XH, Zhuang Q, Qian FJ. Relationship between Serum Lipoprotein Ratios and Insulin Resistance in Polycystic Ovary Syndrome. Int J Endocrinol 2012, 2012:173281. 3389691, 22792101.
10. Wijeyaratne CN, Seneviratne Rde A, Dahanayake S, Kumarapeli V, Palipane E, Kuruppu N, Yapa C, Balen AH. Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic. Hum Reprod 2011, 26(1):202-213. 10.1093/humrep/deq310, 21098627.
11. Li L, Chen X, He Z, Zhao X, Huang L, Yang D. Clinical and Metabolic Features of Polycystic Ovary Syndrome among Chinese Adolescents. J Pediatr Adolesc Gynecol 2012, 25(6):390-395. 10.1016/j.jpag.2012.07.006, 23089573.
12. Hsu M-I. Changes in the PCOS phenotype with age. Steroids 2013, 78(8):761-766. 10.1016/j.steroids.2013.04.005, 23624031.
13. Whigham LD, Butz DE, Dashti H, Tonelli M, Johnson LK, Cook ME, Porter WP, Eghbalnia HR, Markley JL, Lindheim SR, Schoeller DA, Abbott DH, Assadi-Porter FM. Metabolic Evidence of Diminished Lipid Oxidation in Women With Polycystic Ovary Syndrome. Curr Metabolomics 2014, 2(4):269-278. 3994884, 24765590.
14. Dasgupta A, Khan A, Banerjee U, Ghosh M, Pal M, Chowdhury KM, Dasgupta S. Predictors of insulin resistance and metabolic complications in polycystic ovarian syndrome in an eastern Indian population. Indian J Clin Biochem 2013, 28(2):169-176. 10.1007/s12291-012-0253-4, 3613510, 24426204.
15. Yildiz Y, Ozaksit G, Serdar Unlu B, Ozgu E, Energin H, Kaba M, Ugur M. Serum adiponectin level and clinical, metabolic, and hormonal markers in patients with polycystic ovary syndrome. Int J Fertil Steril 2014, 7(4):331-336. 3901186, 24520503.
16. Mehrabian F, Khani B, Kelishadi R, Kermani N. The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females. J Res Med Sci 2011, 16(6):763-769. 3214394, 22091305.
17. Zhao Y, Qiao J. Ethnic differences in the phenotypic expression of polycystic ovary syndrome. Steroids 2013, 78(8):755-760. 10.1016/j.steroids.2013.04.006, 23624030.
18. Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 2009, 15(4):477-488. 10.1093/humupd/dmp008, 19279045.
19. Pourteymour Fard Tabrizi F, Alipoor B, Mehrzad Sadaghiani M, Ostadrahimi A, Malek Mahdavi A. Metabolic Syndrome and Its Characteristics among Reproductive-Aged Women with Polycystic Ovary Syndrome: A Cross-sectional Study in Northwest Iran. Int J Fertil Steril 2013, 6(4):244-249. 3850322, 24520447.
20. Panidis D, Tziomalos K, Misichronis G, Papadakis E, Betsas G, Katsikis I, Macut D. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod 2012, 27(2):541-549. 10.1093/humrep/der418, 22144419.
21. Clark NM, Podolski AJ, Brooks ED, Chizen DR, Pierson RA, Lehotay DC, Lujan ME. Prevalence of Polycystic Ovary Syndrome Phenotypes Using Updated Criteria for Polycystic Ovarian Morphology: An Assessment of Over 100 Consecutive Women Self-reporting Features of Polycystic Ovary Syndrome. Reprod Sci 2014, 21(8):1034-1043. 10.1177/1933719114522525, 24520081.
22. Hosseinpanah F, Barzin M, Keihani S, Tehrani FR, Azizi F. Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS Prevalence Study. Clin Endocrinol (Oxf) 2014, 81(1):93-99. 10.1111/cen.12406, 24428207.
23. Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012, 27(10):3067-3073. 10.1093/humrep/des232, 22777527.
24. Rashidi H, Ramezani Tehrani F, Bahri Khomami M, Tohidi M, Azizi F. To what extent does the use of the Rotterdam criteria affect the prevalence of polycystic ovary syndrome? A community-based study from the Southwest of Iran. Eur J Obstet Gynecol Reprod Biol 2014, 174:100-105.
25. Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F, Azizi F. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol 2011, 9:39. 10.1186/1477-7827-9-39, 3070632, 21435276.
26. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19(1):41-47. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.
27. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004, 18(5):671-683. 10.1016/j.bpobgyn.2004.05.001, 15380140.
28. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004, 89(2):453-462. 10.1210/jc.2003-031122, 14764747.
29. Beydoun HA, Stadtmauer L, Beydoun MA, Russell H, Zhao Y, Oehninger S. Polycystic ovary syndrome, body mass index and outcomes of assisted reproductive technologies. Reprod Biomed Online 2009, 18(6):856-863. 10.1016/S1472-6483(10)60037-5, 2744370, 19490792.
30. Chen X, Yang D, Mo Y, Li L, Chen Y, Huang Y. Prevalence of polycystic ovary syndrome in unselected women from southern China. Eur J Obstet Gynecol Reprod Biol 2008, 139(1):59-64. 10.1016/j.ejogrb.2007.12.018, 18378061.
31. Azizi F, Hadaegh F, Khalili D, Esteghamati A, Hosseinpanah F, Delavari A, Larijani B, Mirmiran P, Zabetian A, Mehrabi Y, Kelishadi R, Aghajani H. Appropriate definition of metabolic syndrome among Iranian adults: report of the Iranian National Committee of Obesity. Arch Iran Med 2010, 13(5):426-428.
32. Alemzadeh R, Kichler J, Calhoun M. Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome. Eur J Endocrinol 2010, 162(6):1093-1099. 10.1530/EJE-10-0205, 20371657.
33. Amato MC, Verghi M, Galluzzo A, Giordano C. The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Hum Reprod 2011, 26(6):1486-1494. 10.1093/humrep/der088, 21447694.
34. Skrha J, Haas T, Sindelka G, Prazny M, Widimsky J, Cibula D, Svacina S. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab 2004, 89(1):135-141. 10.1210/jc.2002-030024, 14715840.
35. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004, 27(6):1487-1495. 10.2337/diacare.27.6.1487, 15161807.